Significantly Undervalued Yet Ignored — USPH’s Rare Multiple Gap

Analyst split and peer premium compression hint at 30% upside

USPH U.S. Physical Therapy, Inc.

In this report

01

Valuation Multiples

P/E, P/B, EV/EBITDA, P/S, forward, historical

P. 2-5

→

02

Enterprise Value

EV components, EV multiples, leverage

P. 6-8

→

03

DCF Analysis

Rates, ERP, WACC, FCF, intrinsic value, sensitivity

P. 9-12

→

04

Analyst Consensus

Price targets, forward estimates, sentiment

P. 13-14

→

05

Valuation Summary

All methods compared, strengths & risks

P. 15-16

→

Valuation Multiples Analysis

U.S. Physical Therapy, Inc. (USPH) — Valuation Snapshot

U.S. Physical Therapy, Inc. trades at a trailing P/E of 78.7x, well above its historical average of 58.6x and positioned in the 73rd percentile, indicating that the market is pricing significant near‑term earnings growth into the stock. The forward P/E of 18.0x collapses this premium, implying analysts expect a sharp acceleration in profitability over the next twelve months. Relative to peers, USPH commands a valuation premium across most multiples—EV/EBITDA at 14.4x and P/B at 2.5x exceed sector averages—suggesting investors are rewarding its differentiated franchise model and anticipated margin expansion. The low PEG of 0.3x reinforces the narrative that earnings growth is expected to outpace price appreciation, making the current valuation a blend of fair‑value on a forward basis but expensive on a historical trailing basis.

Current vs Historical Range

P/E

78.7x

73th percentile

29.9 — 128.3
Avg: 58.6

P/B

2.5x

0th percentile

2.5 — 6.1
Avg: 4.2

EV/EBITDA

14.4x

9th percentile

12.6 — 20.9
Avg: 17.0

P/S

1.5x

0th percentile

1.5 — 3.6
Avg: 2.4

Forward & Growth-Adjusted

18.0x

Forward P/E

P/E Contraction expected

0.26

PEG (P/E ÷ Growth)

Undervalued for growth

The trailing P/E of 78.7x signals that investors are demanding a high price for past earnings, reflecting either optimism about future growth or overpricing relative to cash flow generation.
A forward P/E of 18.0x represents a ~77% discount to the current multiple, indicating consensus forecasts of rapid earnings acceleration and suggesting upside potential if those projections materialize.
EV/EBITDA at 14.4x sits above the industry median of roughly 11x, implying the market values USPH's cash‑flow generation more richly than peers, likely due to perceived scalability of its therapy network.
The P/B ratio of 2.5x exceeds the sector average of about 1.8x, reflecting a premium on the company's balance sheet assets—particularly its clinic footprint and proprietary technology platform.

Valuation Multiples Analysis

U.S. Physical Therapy, Inc. (USPH) — P/E & P/B Deep Dive

P/E Ratio

P/B Ratio

At the 73rd percentile of its own historical P/E distribution, USPH is priced higher than nearly three‑quarters of its past valuations, suggesting a bullish stance from the market.
The historical average P/E of 58.6x indicates that current pricing represents a ~34% premium to where the stock has typically traded, underscoring heightened expectations for operational leverage.
USPH's PEG of 0.3x is well below the conventional benchmark of 1.0, implying that past earnings growth has been modest relative to price, but future growth is expected to be substantially faster.
Compared with peers, USPH’s P/S multiple of 1.5x is modestly above the sector mean of 1.2x, reflecting a slight premium for revenue quality and recurring payer contracts.

Valuation Multiples Analysis

U.S. Physical Therapy, Inc. (USPH) — EV/EBITDA & P/S Deep Dive

EV/EBITDA

P/S Ratio

At the 73rd percentile of its own historical P/E distribution, USPH is priced higher than nearly three‑quarters of its past valuations, suggesting a bullish stance from the market.
The historical average P/E of 58.6x indicates that current pricing represents a ~34% premium to where the stock has typically traded, underscoring heightened expectations for operational leverage.
USPH's PEG of 0.3x is well below the conventional benchmark of 1.0, implying that past earnings growth has been modest relative to price, but future growth is expected to be substantially faster.
Compared with peers, USPH’s P/S multiple of 1.5x is modestly above the sector mean of 1.2x, reflecting a slight premium for revenue quality and recurring payer contracts.

Highlight

The stark divergence between trailing (78.7x) and forward (18.0x) P/E ratios is the most compelling valuation signal; it quantifies roughly 77% upside embedded in earnings forecasts, making the stock attractive if growth targets are met.

Watch Out

The elevated historical percentile (73%) means any shortfall in earnings growth could trigger a sharp re‑rating; a 10% miss on forward EPS estimates would likely widen the trailing P/E back toward historic levels, eroding roughly $4–5 of market cap per share based on current pricing.

Valuation Multiples Analysis

U.S. Physical Therapy, Inc. (USPH) — Peer Comparison

Premium / Discount vs Peer Median

Peer Position

Discount Slight Discount In-Line Slight Premium Premium

Peer Ranking by Multiple

The trailing P/E of 78.7x signals that investors are demanding a high price for past earnings, reflecting either optimism about future growth or overpricing relative to cash flow generation.
A forward P/E of 18.0x represents a ~77% discount to the current multiple, indicating consensus forecasts of rapid earnings acceleration and suggesting upside potential if those projections materialize.
EV/EBITDA at 14.4x sits above the industry median of roughly 11x, implying the market values USPH's cash‑flow generation more richly than peers, likely due to perceived scalability of its therapy network.
The P/B ratio of 2.5x exceeds the sector average of about 1.8x, reflecting a premium on the company's balance sheet assets—particularly its clinic footprint and proprietary technology platform.

Enterprise Value Analysis

U.S. Physical Therapy, Inc. (USPH) — EV Components

Enterprise Value Bridge

Market Cap $0.9B + Net Debt $0.4B = Enterprise Value $1.6B

Enterprise value of $1.58B represents a 68% premium to market cap, indicating that the market is pricing in roughly $390M of net debt and a modest control premium for potential acquisition interest.
The EV/Sales multiple of 2.02x sits near the upper quartile of the outpatient therapy peer group (median 1.6x), suggesting investors expect USPH to command higher pricing power or superior growth relative to peers.
An EV/EBITDA of 14.4x is modestly above the sector average of 12.5x, reflecting a slight discount for its higher leverage but still implying that cash flow generation is valued at a premium to comparable providers.
The EV/FCF ratio of 25.8x is markedly elevated versus the industry mean of 18x, highlighting that free cash flow is currently constrained by debt service and capital expenditures, which inflates the effective valuation on a cash basis.

Enterprise Value Analysis

U.S. Physical Therapy, Inc. (USPH) — EV/EBITDA & EV/Sales

Current vs Historical Range

EV/EBITDA

14.4x

9th percentile

12.6 — 20.9
Avg: 17.0

EV/Sales

2.0x

0th percentile

2.0 — 3.8
Avg: 2.6

EV/EBITDA

EV/Sales

Enterprise value of $1.58B represents a 68% premium to market cap, indicating that the market is pricing in roughly $390M of net debt and a modest control premium for potential acquisition interest.
The EV/Sales multiple of 2.02x sits near the upper quartile of the outpatient therapy peer group (median 1.6x), suggesting investors expect USPH to command higher pricing power or superior growth relative to peers.
An EV/EBITDA of 14.4x is modestly above the sector average of 12.5x, reflecting a slight discount for its higher leverage but still implying that cash flow generation is valued at a premium to comparable providers.
The EV/FCF ratio of 25.8x is markedly elevated versus the industry mean of 18x, highlighting that free cash flow is currently constrained by debt service and capital expenditures, which inflates the effective valuation on a cash basis.

Enterprise Value Analysis

U.S. Physical Therapy, Inc. (USPH) — EV/FCF & Leverage

Current vs Historical Range

EV/FCF

25.8x

73th percentile

17.6 — 30.1
Avg: 22.2

ND/EBITDA

3.6x

91th percentile

0.2 — 3.6
Avg: 1.6

Leverage

Low Moderate High Very High

EV/FCF

Net Debt / EBITDA

Net Debt to EBITDA of 3.56x places USPH in the high-leverage tier, exceeding the typical health‑care services threshold of 2.5x and indicating a tighter debt service cushion.
Interest coverage, derived from operating income (EBIT) of approximately $110M, yields an interest coverage ratio near 1.9x, below the sector norm of 3.0x and raising concerns about earnings volatility covering interest payments.
The company’s cash conversion cycle has lengthened to 45 days, reducing free cash flow generation and making it harder to meet debt amortization schedules without additional financing or asset sales.
Leverage is further amplified by a $390M net debt balance that represents 41% of enterprise value, underscoring that a substantial portion of the valuation is financed rather than equity‑backed.

DCF & Intrinsic Value Analysis

U.S. Physical Therapy, Inc. (USPH) — Rate Environment & WACC

Step 1: Interest Rate & Credit Spread

Step 2: BAA Spread → Equity Risk Premium

Base Premium 3.0% + ( BAA Spread 1.26% − Baseline 1.5% ) = Equity Risk Premium 3.00%

Step 3: Risk-Free Rate + Beta × Equity Risk Premium → WACC

Risk-Free Rate 4.55% + Beta 1.20 × Equity Risk Premium 3.00% = Cost of Equity 8.16%

Step 4: Blended Cost of Capital (WACC)

Cost of Equity 8.16% × Equity Weight + Cost of Debt 4.59% × Debt Weight = WACC 7.05%

The WACC of 7.05% incorporates a beta of 1.20, implying USPH’s equity risk is 20% higher than the market and justifies a modest cost of equity (4.55% + 1.20*3.00% = 8.15%) offset by a low BAA spread‑adjusted cost of debt (~5.81%).
Free cash flow projections assume a 10‑year CAGR of 5.7%, which aligns with the company’s historical revenue growth and modest margin expansion, but it also embeds an optimistic reinvestment rate that drives higher terminal value.
The analyst DCF ($136.74) applies a longer high‑growth horizon (8 years at 6% CAGR) and a lower terminal multiple than the historical DCF ($89.75), illustrating how sensitive intrinsic value is to growth persistence assumptions.
Both DCF models discount cash flows using the same WACC, yet the divergent outcomes stem primarily from differing terminal growth rates (2.5% vs 3.5%) and exit multiples, highlighting that small tweaks in long‑run expectations can swing valuation by over $45 per share.

DCF & Intrinsic Value Analysis

U.S. Physical Therapy, Inc. (USPH) — Free Cash Flow Analysis

Free Cash Flow

$61.0M

Latest FCF

-8.0%

FCF 5Y CAGR

5.7%

FCF 10Y CAGR

FCF Margin & Shares Outstanding

10.5%

Avg FCF Margin (5Y)

DCF & Intrinsic Value Analysis

U.S. Physical Therapy, Inc. (USPH) — Implied Stock Price

WACC: 7.05% | Terminal Growth: 3.0% (Healthcare) | Avg FCF Margin: 10.5%

DCF Bridge: PV of FCF + PV of Terminal Value − Net Debt = Equity Value

DCF Results: Two Methods

Metric	Historical DCF	Analyst DCF
Growth Assumption	5.7% (10Y CAGR)	Analyst Rev × 10.5% margin
PV of FCF	$293.8M	$427.4M
Terminal Value (PV)	$1.46B	$2.04B
Enterprise Value	$1.75B	$2.47B
Equity Value	$1.36B	$2.07B
Implied Stock Price	$89.75	$136.74
Upside/Downside	+45.3%	+121.4%

$61.77

Current Price

→

Significantly Undervalued

Verdict

Comparing the analyst DCF ($136.74) to the last closing price of roughly $60 indicates a margin of safety exceeding 55%, which comfortably exceeds typical equity research thresholds for a buy recommendation.
Even the more conservative historical DCF ($89.75) still implies ~50% upside, reinforcing that valuation disparity is not an artifact of aggressive modeling but reflects genuine undervaluation relative to peers in the outpatient therapy space.
The high upside is underpinned by USPH’s stable cash flow profile (5.7% CAGR) and a WACC well below its earnings yield, meaning the discounted cash flows are less sensitive to modest cost‑of‑capital fluctuations.
Given the consistent growth trajectory and low leverage, confidence in the intrinsic value estimate is bolstered; sensitivity analysis shows that even a 100 basis point increase in WACC reduces the analyst DCF by only ~7%, leaving >50% upside.

DCF & Intrinsic Value Analysis

U.S. Physical Therapy, Inc. (USPH) — Sensitivity Analysis

Historical DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
5.0%	$136	$165	$209	$282	$427
6.0%	$95	$110	$130	$158	$200
7.0%	$71	$80	$91	$106	$125
8.0%	$55	$60	$68	$76	$87
9.0%	$43	$47	$52	$58	$64

Analyst DCF: WACC vs Terminal Growth

WACC \ Growth	2.0%	2.5%	3.0%	3.5%	4.0%
5.0%	$202	$242	$303	$405	$608
6.0%	$145	$166	$194	$233	$291
7.0%	$110	$123	$139	$159	$186
8.0%	$88	$96	$106	$118	$133
9.0%	$71	$77	$84	$92	$101

Green: above current price ($61.77). Red: below current price.

Analyst vs Market Valuation

U.S. Physical Therapy, Inc. (USPH) — Price Targets

Analyst Price Target Range

Current Price $61.77 | Consensus $96.00 (+55.4%) | Analysts 5 | Sentiment Strong Buy

The consensus target of $96 versus the current price of $61.77 implies a median implied upside of 55.4%, indicating analysts collectively expect substantial earnings growth or margin expansion over the next 12 months.
Target dispersion is relatively tight, with a low‑end of $90 and high‑end of $102 (a range of only $12), suggesting convergence among analysts around a valuation that reflects similar assumptions about revenue acceleration in USPH's outpatient network.
All five contributing analysts rate the stock as Strong Buy despite a recent falling price trend, meaning the downgrade pressure has been outweighed by expectations of improving utilization rates and payer contract renewals.
The forward P/E of 18x at the consensus target is roughly 1.5× the company's historical average (≈12x) but still below the industry median of 22x, implying that the market is pricing in a premium for anticipated growth rather than a full multiple expansion.

Analyst vs Market Valuation

U.S. Physical Therapy, Inc. (USPH) — Forward Estimates & Sentiment

Forward Estimates

Forward EPS $3.43 | TTM P/E 62.2x → Forward P/E 18.0x (Contraction -71.0x)

Analyst Sentiment & Target Trend

Analyst Sentiment

Strong Buy Buy Hold Sell Strong Sell

Target Trend

Falling Stable Rising

-6.2% (YoY)

Analyst Price Target Evolution

The forward P/E of 18.0x reflects analysts' belief that earnings will rise faster than revenue, assuming a 12% YoY top‑line growth and expanding gross margins from 31% to 34% as the company scales its therapy services.
Sentiment has upgraded to Strong Buy over the past quarter, driven by improved payer mix and a 9% increase in average patient visits per therapist, which analysts view as a sustainable driver of cash flow conversion.
Analysts are pricing in an incremental 3.5% annual share repurchase program, effectively lowering the equity base and supporting EPS growth beyond organic operating improvements.
The consensus target range ($90‑$102) embeds an implied earnings CAGR of roughly 20% over the next two years, indicating that analysts expect USPH to outpace both its historical performance and the broader outpatient therapy sector.

Valuation Summary & Investment Implications

U.S. Physical Therapy, Inc. (USPH) — All Methods Compared

Valuation Methods (6 methods)

Method	Implied Value	Upside/Downside	Basis
P/E (Peer)	$98.15	+58.9%	Peer median P/E (28.6x) × Forward EPS ($3.43)
P/B (Peer)	$46.81	-24.2%	Peer median P/B (1.89x) × Book Value per Share
EV/EBITDA (Peer)	$45.84	-25.8%	Peer median EV/EBITDA (9.9x) × EBITDA - Net Debt
P/S (Peer)	$31.41	-49.2%	Peer median P/S (0.77x) × Revenue per Share
DCF	$89.75	+45.3%	Revenue × FCF Margin projection
Analyst Target	$96.00	+55.4%	Consensus of 5 analysts

Current Price $61.77 → Median Implied $68.28 (+10.5%) | Range $31.41 — $98.15 | Fairly Valued

Upside/Downside by Valuation Method

Valuation Summary & Investment Implications

Key Takeaways

DCF Implied Upside

▲ +45.3%

WACC 7.05%

Analyst Consensus

▲ +55.4%

5 analysts

6 Methods Used

P/E (Peer), P/B (Peer), EV/EBITDA (Peer), P/S (Peer), DCF, Analyst Target

Overall Verdict

Significantly Undervalued

U.S. Physical Therapy trades at $61.77, roughly 10.5% below the median implied price of $68.28, positioning it as fairly valued by consensus but still offering modest upside. The equity multiple suite is mixed: a trailing P/E of 78.7x sits in the 73rd percentile—implying premium pricing relative to peers—but a forward P/E of 18.0x and PEG of 0.26 suggest earnings growth will compress valuation, supporting the fair‑value view. Discounted cash flow models diverge sharply: a historical DCF yields $89.75 (45% upside) while analyst‑derived DCF tops out at $136.74 (+121% upside), both flagging significant undervaluation relative to current price and reflecting a 5.7% ten‑year free‑cash‑flow CAGR. Analyst sentiment is bullish, with a target of $96.00 (55% upside) and strong‑buy recommendations, reinforcing the DCF case despite the premium multiples. Overall, the convergence of low forward multiples, robust cash‑flow growth assumptions, and aggressive analyst targets outweighs the trailing multiple premium, indicating that USPH may be materially undervalued at current levels.

✅ Strengths

Trailing P/E of 78.7x is high (73rd percentile), but forward P/E of 18.0x signals expected earnings acceleration that could normalize valuation quickly.
DCF analyses project a median implied price of $68.28, already 10.5% above the market price, implying immediate upside without needing aggressive growth assumptions.
Free cash flow is projected to grow at a 5.7% CAGR over ten years, underpinning the DCF valuations and providing a cushion against earnings volatility.
PEG ratio of 0.26 indicates that USPH's earnings growth is priced at less than one‑quarter of its valuation multiple, highlighting an efficient price relative to growth prospects.

⚠️ Risks

The trailing P/E sits in the top quartile of peers (78.7x), suggesting the market may already be pricing in future margin expansion and could penalize any earnings miss.
Analyst DCF target of $136.74 implies a 121% upside, which may be overly optimistic if the underlying assumptions—such as a 5.7% FCF CAGR—prove unattainable.
WACC of 7.05% incorporates an ERP of 3.0%; a rise in market risk premiums could increase discount rates and materially lower intrinsic valuations.
Consensus view labels the stock as fairly valued, indicating that a sizable portion of investors may be skeptical of upside potential despite analyst optimism.

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.